Tolebrutinib

Phase 3

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Primary Progressive Multiple Sclerosis

Drug Information

Target Indication

Primary Progressive Multiple Sclerosis

Clinical Trial

Last updated: 12/7/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Regulatory Approvals

EMA6/19/2026

Cenrifki

Cenrifki is indicated for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) without relapses in the last 2 years.

Drug Science

Mechanism of action & safety profile

Developer

SNY

Sanofi

Related Pipeline

Sleep Initiation and Maintenance Disorders

Hemophilia A

Ulcerative Colitis

Alzheimer Disease

Influenza

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts